ABSTRACT Subcutaneous adrenaline and terbutaline have been compared in a double blind study of 20 patients with acute severe asthma presenting to an accident and emergency department. Ten patients received adrenaline 05 mg (0 5 ml) and 10 terbutaline 05 mg (05 ml) subcutaneously. Further treatment with nebulised salbutamol (5 mg), hydrocortisone (200 mg), and aminophylline (0-9 mg/kg/hour) was started 15 minutes later. All patients reported a reduction in chest tightness within three minutes of receiving both adrenaline and terbutaline and reported no adverse effects. Mean baseline values of peak expiratory flow (PEF) and forced expiratory volume in one second (FEV1) did not differ significantly between the adrenaline group (130 1 min-' and 0-83 1) and the terbutaline group (111I min-' and 0 63 1). After administration of adrenaline PEF had increased by 21% and FEV, by 40% five minutes after the injection, and by 35% and 64% at 15 minutes. Terbutaline caused a 23% increase in PEF and a 37% increase in FEV, at five minutes, and a 40% and 58% increase at 15 minutes. There was no significant difference in PEF, FEV,, heart rate, blood pressure, or pulsus paradoxus between the two groups at any time. Continuous electrocardiographic recording showed no abnormalities in either group. Thus in this study subcutaneous adrenaline (0 5 mg) and terbutaline (0 5 mg) produced effective rapid bronchodilatation without serious side effects.
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About 1500 patients continue to die from asthma each year in England and Wales,' despite self referral to hospital and intensive conventional treatment. Many factors are responsible for this, but one major problem is that severe attacks may start abruptly, often late at night or in the early morning.2"5 Our study was stimulated by the death of two young asthmatic women6 who were known to be "at risk" and for whom we had taken every precaution. Both had had abrupt attacks of asthma, developing within minutes and not responding to pressurised aerosol bronchodilators. Both died despite urgent hospital admission.
There are few reports267 supporting the use of self administration of parenteral adrenaline or selective 2 adrenergic drugs in acute asthmatic attacks. Adrenaline appears to have lost favour8 because of the fear of adverse effects such as tachycardia, ventricular ectopic beats, hypertension, pulmonary oedema, tremor, sweating, and headaches, and even death." A closer look at these reports shows that most do not cite the original papers and most of the adverse effects quoted stem from early observations of adrenaline in status Accepted 21 September 1987 asthmaticus, when high doses-such as 4-10 mg (4-10 ml of 1:1 000)-of adrenaline were given.'2 '3 We therefore designed a study to compare the efficacy and safety of subcutaneous adrenaline and terbutaline as first line treatment for patients with acute severe attacks of asthma presenting to the accident and emergency department. Permission for the study was obtained from the ethical practice subcommittee, and informed consent was obtained from every patient.
Methods

PATIENTS
Twenty patients aged 10-65 years were enrolled in the study ( 
Discussion
In 1977 Crompton" discussed in detail the difficulties of carrying out clinical trials in patients with severe asthma and the problem of recruiting suitable patients before they had received conventional emergency treatment. We tried to ensure that every patient with acute severe asthma presenting to the accident and emergency department at any time of day would be referred for the study before being given nebulised or intravenous treatment. Placebo control was not included as all our subjects had acute severe asthma that required immediate relief; without a placebo we cannot be sure that all of the response seen after administration of adrenaline and terbutaline was due to the drugs, but the rapid subjective and objective improvement that followed the two drugs suggests that most if not all of the response was produced by the drugs. We found that 0-5 mg adrenaline given subcutaneously was as effective as 0 5 mg subcutaneous terbutaline, and neither caused side effects in these patients. Subjective relief was noted within a mean time of three minutes from the injection, and this was reflected by improvement in pulmonary function No adverse effects were noted with either drug at any time during the treatment. Less controlled clinical studies, without electrocardiographic monitoring,7""'' have shown no significant difference in bronchodilatation between parenteral adrenaline and terbutaline, and none has reported appreciable side effects. In this study further bronchodilatation occurred after inhalation of nebulised salbutamol and intravenous infusion of hydrocortisone and aminophylline. This has been observed with combined treatment previously,20 but possibly some of the additional improvement reflects the continuing action ofsubcutaneous adrenaline (maximum effect 30 minutes'2) or terbutaline (maximum effect 30-60 minutes2').
Barger and Dale in 191022initiated the use of subcutaneous adrenaline for patients with acute asthma. Adrenaline may cause bronchodilatation through ,B adrenoceptor agonism23 and via its a adrenergic action, producing decongestion of the bronchial mucosa.24 Adverse reports of anxiety, tremor, hypertension, palpitations, and cardiac arrhythmias and even death" have also been attributed to a and P adrenergic stimulation. Having checked these reports we believe that side effects may have been overemphasised, since they have often been associated with the use of massive doses of adrenaline, fast administration, and inadvertent intravenous injection.'2 Side effects such as palpitations and tremor with smaller doses (0 5 mg) of the drug have been minimal and have not been considered to be a problem by the patient in view of the quick and complete relief from asthma.25 26 Traditionally, caution is urged in the use of adrenaline or / adrenoceptor agonists in the elderly. When subcutaneous adrenaline 0-5 mg was given to 100 asthmatic patients aged 50-80 years and 25 young asthmatic patients aged 23-37 years widespread electrocardiographic changes were seen in over half the elderly patients but in only one of the young patients. Among the elderly patients 27 had angina, 13 hypertension, and nine cardiomegaly. 27 Although drugs such as terbutaline and salbutamol are #2 selective, they are not free of adverse effectssome effects indeed, such as tachycardia and tremor, being similar to those seen with adrenaline. '7 In some studies heart rate changes with terbutaline have exceeded those that followed adrenaline,28 and this was for the same amount ofbronchodilatation in one study of asthmatic patients.7 Dose-response curves for the two drugs have not, however, been compared and bronchodilator equivalence has not been established.
In conclusion, we found that both adrenaline and terbutaline (0 5 mg) given subcutaneously gave rapid and effective bronchodilatation in patients with acute severe asthma with no important side effects. The response was rapid, occurring within three minutes.
Spiteri, Millar, Pavia, Clarke Subcutaneous administration of either drug by self administration may be of value to patients prone to abrupt attacks of asthma. Further work is needed but, on the basis of our results and review of the published reports, we believe that subcutaneous administration of both terbutaline and adrenaline is less hazardous than hitherto believed.
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